Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

Table 1

Patient baseline demographics and disease characteristics of patients who started the pretreatment session.

	Atazanavir/ritonavir 300/100 mg qd + one NRTI + etravirine 200 mg bid ()	Atazanavir/ritonavir 400/100 mg qd + one NRTI + etravirine 200 mg bid ()	All patients; ()
Female [ (%)]	12 (48.0)	13 (52.0)	25 (50.0)
Age, years [median (range)]	39.0 (26–63)	40.0 (18–56)	40.0 (18–63)
Race [ (%)]
Black or African-American	12 (48.0)	18 (72.0)	30 (60.0)
Asian	6 (24.0)	2 (8.0)	8 (16.0)
White	6 (24.0)	5 (20.0)	11 (22.0)
Others	1 (4.0)	0	1 (2.0)
Country [ (%)]
South Africa	9 (36.0)	13 (52.0)	22 (44.0)
USA	10 (40.0)	8 (32.0)	18 (36.0)
Thailand	6 (24.0)	2 (8.0)	8 (16.0)
Argentina	0	2 (8.0)	2 (4.0)
Prebaseline (copies/mL) [median (range)]	4.1 (2–6)	4.1 (2–6)	4.1 (2–6)
Prebaseline CD4^+ cell count, median (range), cells/mm^3	186 (8–678)	238 (55–1061)	223 (8–1061)
Duration of HIV infection, years (median (range))	7.2 (2–16)	6.7 (1–26)	7.0 (1–26)
CDC clinical stage of infection [ (%)]
A	10 (40.0)	9 (36.0)	19 (38.0)
B	7 (28.0)	7 (28.0)	14 (28.0)
C	8 (32.0)	9 (36.0)	17 (34.0)
Mode of HIV infection [ (%)]
Heterosexual contact	15 (60.0)	12 (48.0)	27 (54.0)
Heterosexual contact/MSM	1 (4.0)	1 (4.0)	2 (4.0)
MSM	5 (20.0)	5 (20.0)	10 (20.0)
Others	4 (16.0)	7 (28.0)	11 (22.0)

CDC: Centers for Disease Control and Prevention; MSM: men who have sex with men; : number of patients per treatment group; (%): number (proportion) of patients with specified parameter; NRTI: nucleoside reverse transcriptase inhibitor; VL: viral load.
Prebaseline: Day 1 of the pretreatment period.